Latest News


The SEAS Trial Debated

Medscape | 28 minutes ago

While numerous experts say the results provide little new information and won't alter clinical practice, some see the data as positive for Vytorin, especially in light of the wealth of evidence showing the benefit of lowering LDL-cholesterol levels.... (more)


ABC News: Drugs Add 13 Years to Lives of HIV Patients

ABC News | 2 hours 1 minute ago

WASHINGTON (Reuters) - Cocktails of HIV drugs help patients live an average of 13 years longer -- if they are lucky enough to get them, researchers reported on Thursday.BRASILIA, BRAZIL: Bottles of Kaletra, of the Abbott Laboratories, are displayed at a pharmacy in... BRASILIA, BRAZIL: Bottles of Kaletra, of the Abbott Laboratories, are displayed at a pharmacy in Brasilia, 30 June 2005. Brazilian Health Minister Humberto Costa said Monday he was aiming to halve the cost of Kaletra, a key HIV...... (more)


Pfizer fined for lying about rival's products

Sydney Morning Herald, The | 2 hours 7 minutes ago

THE pharmaceutical giant Pfizer has been fined a record $200,000 after its representatives told doctors that a rival company's anti-cholesterol product was associated with kidney problems. - Sydney Morning Herald Online... (more)


Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal Transduction*

Journal of Biological Chemistry | 2 hours 29 minutes ago

The small leucine-rich proteoglycan (SLRP) family has significantly expanded in the past decade to now encompass five discrete classes, grouped by common structural and functional properties.... (more)


Osiris stem cell line sale OK'd

Sun (Baltimore), The | 7 hours 48 minutes ago

Osiris Therapeutics' shareholders approved yesterday the sale of the stem cell drugmaker's only product line, a bone-regeneration treatment called Osteocel, in a transaction worth up to $137 million, which will be used for the company's next generation of drugs.... (more)


Harvard stem cell research gets boost

Boston Globe, The | 11 hours 8 minutes ago

British drug giant GlaxoSmithKline has agreed to sponsor at least $25 million in work at the Harvard Stem Cell Institute in Cambridge, one of the largest investments in stem cell research ever by a major pharmaceuticals company.... (more)


Genentech Reviews Roche Takeover Bid

Wall Street Journal, The | 11 hours 13 minutes ago

Genentech Inc. said late Thursday it won't act on Roche Group AG's $89-a-share takeover bid until the deal is evaluated by a special committee of three members of its board.... (more)


Genentech Weighs Takeover - NYTimes.com

New York Times, The | 13 hours 13 minutes ago

Genentech said Thursday that the company had formed a special committee, consisting of its three independent board members, to consider a takeover bid from Roche Holding. The committee’s chairman, Charles A. Sanders, called Roche’s offer “unsolicited and unexpected.” On Monday, Roche announced a bid of $89 a share for the 44 percent of Genentech stock it did not own.... (more)


Affymetrix cuts full-year revenue outlook

Forbes | 14 hours 37 minutes ago

SANTA CLARA, Calif. - Affymetrix Inc., which makes the GeneChip system for genetic data analysis, cut its full-year revenue outlook because of weakness in its pharmaceutical business, sending shares in a nosedive during after-hours trading.... (more)


Affymetrix swings to 2Q loss on revenue decline

Forbes | 14 hours 37 minutes ago

SANTA CLARA, Calif. - Affymetrix Inc., which makes the GeneChip system for genetic data analysis, said Thursday it swung to a second-quarter loss on lower revenue and a restructuring charge.... (more)


Genentech convenes committee to consider Roche bid

Forbes | 14 hours 37 minutes ago

SOUTH SAN FRANCISCO, Calif. - Genentech Inc. says the company has officially formed a special committee consisting of its three independent board members to consider Roche Holding's takeover bid.... (more)


Genentech committee reviewing Roche offer

Reuters | 15 hours 12 minutes ago

By Deena BeasleyLOS ANGELES (Reuters) - Genentech Inc (DNA.N: Quote, Profile, Research, Stock Buzz) said on Thursday a special committee of its three independent directors is assessing the proposal from Roche AG (ROG.VX: Quote, Profile, Research, Stock Buzz) to acquire the shares of the biotechnology company it does not already own.... (more)




 1  2  3  4  5  6  7  8  9 ...   Next >

191 Stories  |   RSS Feed



Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more

Latest Blog Postsview more


Companies in the news